<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043</article-id>
<article-id pub-id-type="publisher-id">PONE-D-22-16315</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Disease surveillance</subject><subj-group><subject>Infectious disease surveillance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Medical conditions</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Infectious disease control</subject><subj-group><subject>Infectious disease surveillance</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Medical conditions</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Africa</subject><subj-group><subject>Tanzania</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Pandemics</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019</article-title>
<alt-title alt-title-type="running-head">Evaluation of the influenza-like illness sentinel surveillance system in Tanzania, 2019</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1939-2492</contrib-id>
<name name-style="western">
<surname>Shedura</surname>
<given-names>Vulstan James</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6674-7487</contrib-id>
<name name-style="western">
<surname>Hussein</surname>
<given-names>Ally Kassim</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Nyanga</surname>
<given-names>Salum Kassim</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kamori</surname>
<given-names>Doreen</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4640-0486</contrib-id>
<name name-style="western">
<surname>Mchau</surname>
<given-names>Geofrey Joseph</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences (SPHSS), Dar es Salaam, Tanzania</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Tanzania Field Epidemiology and Laboratory Training Program (TFELTP), Dar es Salaam, Tanzania</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>National Public Health Laboratory, Dar es Salaam, Tanzania</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Tanzania Food and Nutrition Centre (TFNC), Dar es Salaam, Tanzania</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Meseko</surname>
<given-names>Clement Adebajo</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>National Veterinary Research Institute, NIGERIA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">vulstanshedura@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>3</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>18</volume>
<issue>3</issue>
<elocation-id>e0283043</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>6</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>2</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>Shedura et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0283043"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>The World Health Organization (WHO) recommends periodic evaluations of influenza surveillance systems to identify areas for improvement and provide evidence of data reliability for policymaking. However, data on the performance of established influenza surveillance systems are limited in Africa, including Tanzania. We aimed to assess the usefulness of the Influenza surveillance system in Tanzania and to ascertain if the system meets its objectives, including; estimating the burden of disease caused by the Influenza virus in Tanzania and identifying any circulating viral strains with pandemic potential.</p>
</sec>
<sec id="sec002">
<title>Methodology</title>
<p>From March to April 2021, we collected retrospective data through a review of the Tanzania National Influenza Surveillance System electronic forms for 2019. Furthermore, we interviewed the surveillance personnel about the system’s description and operating procedures. Case definition (ILI-Influenza Like Illness and SARI-Severe Acute Respiratory Illness), results, and demographic characteristics of each patient were obtained from the Laboratory Information System (Disa*Lab) at Tanzania National Influenza Center. The United States Centers for disease control and prevention updated guidelines for evaluating public health surveillance systems were used to evaluate the system’s attributes. Additionally, the system’s performance indicators (including turnaround time) were obtained by evaluating Surveillance system attributes, each being scored on a scale of 1 to 5 (very poor to excellent performance).</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>A total of 1731 nasopharyngeal and oropharyngeal samples were collected from each suspected influenza case in 2019 from fourteen (14/14) sentinel sites of the influenza surveillance system in Tanzania. Laboratory-confirmed cases were 21.5% (373/1731) with a predictive value positive of 21.7%. The majority of patients (76.1%) tested positive for Influenza A. Thirty-seven percent of patients’ results met the required turnaround time, and 40% of case-based forms were incompletely filled. Although the accuracy of the data was good (100%), the consistency of the data was below (77%) the established target of ≥ 95%.</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>The overall system performance was satisfactory in conforming with its objectives and generating accurate data, with an average performance of 100%. The system’s complexity contributed to the reduced consistency of data from sentinel sites to the National Public Health Laboratory of Tanzania. Improvement in the use of the available data could be made to inform and promote preventive measures, especially among the most vulnerable population. Increasing sentinel sites would increase population coverage and the level of system representativeness.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The author(s) received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files (<xref ref-type="supplementary-material" rid="pone.0283043.s005">S4-File</xref>).</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p><italic>Influenza</italic> is an acute viral respiratory tract disease characterized by fever, headache, myalgia, prostration, coryza, sore throat, and cough. Cough is often severe and prolonged, with recovery in 2–7 days [<xref ref-type="bibr" rid="pone.0283043.ref001">1</xref>]. The World Health Organization (WHO) estimates that seasonal influenza causes 3 to 5 million cases of severe influenza disease and may result in 290 000–650 000 deaths yearly due to respiratory diseases alone [<xref ref-type="bibr" rid="pone.0283043.ref002">2</xref>]. In 2008, Tanzania initiated the National Influenza Sentinel Surveillance System (NISSS), whereby on July 4, 2009, the first case was reported [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>], and since then, epidemics have been reported and monitored. Currently, the documented prevalence of seasonal influenza in Tanzania is 8.0%, and according to the first surveillance evaluation done in 2010 (30 months after the initiation of the surveillance system), patients increased during the cold and rainy seasons [<xref ref-type="bibr" rid="pone.0283043.ref004">4</xref>].</p>
<p>Global influenza surveillance, coordinated by WHO under the Global Influenza Surveillance and Response System (GISRS) Network, is key to monitoring global trends of seasonal influenza virus circulation, guiding strain selection for annual influenza vaccine composition, monitoring the acquisition of resistance to antiviral drugs, detecting the emergence of influenza viruses with pandemic potential, and monitoring the spread and impact of pandemic influenza viruses [<xref ref-type="bibr" rid="pone.0283043.ref005">5</xref>].</p>
<p>The GISRS network was initiated in 1952 by the WHO as a response strategy against influenza disease [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>]. WHO recommends using standard case definitions and procedures for global influenza surveillance among outpatients and inpatients and periodic comprehensive evaluations of established surveillance systems, beginning 1–2 years after implementation [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>].</p>
<p>The NISSS in Tanzania operates through an organizational structure that involves the sentinel sites, the National Public Health Laboratory (NPHL), the epidemiology section of the Tanzania Ministry of Health (MoH), and collaborative surveillance partners (WHO and Centers for disease control and prevention (CDC) (see <xref ref-type="supplementary-material" rid="pone.0283043.s001">S1 Fig</xref>).</p>
<p>Sentinel sites are hospitals or health centers, and each has a surveillance focal person who coordinates the functioning of the surveillance activity, linking and reporting to NPHL and the Epidemiology section at the MoH. The main functions of a sentinel site are to enroll patients for surveillance, collect epidemiological and laboratory data, perform data entry and simple analysis and submit collected Case-Based Forms (CBF) and laboratory specimens to the Epidemiology section of the MoH and NPHL, respectively [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>]. NPHL, as a National Influenza Center (NIC) of Tanzania, has the role of supporting laboratory capacity for the surveillance system at the central level (MoH) and sentinel sites [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>]. The Epidemiology Section of the MoH is responsible for the overall coordination, staff training, response, procurement of equipment and consumables, monitoring and evaluation, and providing feedback to all levels. They are also primarily responsible for data management, analysis, and dissemination of reports to stakeholders [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>].</p>
<p>The overall responsibilities of collaborative partners are to contribute to technical assistance and provide resource support for running surveillance activities [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>]. The primary purpose of implementing an influenza sentinel surveillance system includes: determining the characteristics of circulating Influenza viruses as well as detecting and ascertaining any new strains with pandemic potential [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>].</p>
<p>Although influenza sentinel surveillance has been established in several African countries, data about the performance of established surveillance systems are limited on the continent and especially in Tanzania [<xref ref-type="bibr" rid="pone.0283043.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0283043.ref008">8</xref>]. Such evaluations enable countries to assess the performance of their surveillance systems, identify areas for improvement and provide evidence of data reliability for policymaking and public health interventions as well as compliance with international surveillance standards. This study aimed to evaluate the NISSS in Tanzania by determining whether the NISSS complies with its objectives stated in the protocol for the national influenza sentinel surveillance system [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>]. It also evaluated the system’s attributes and usefulness and provided relevant recommendations for improvement. Findings from this evaluation will help to improve the performance of the influenza surveillance system in Tanzania and other similar resource-limited settings.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<p>We described the attributes and usefulness of the NISSS of Tanzania using a descriptive cross-sectional survey. We extracted and evaluated routinely recorded ILI and SARI data between January and December 2019.</p>
<sec id="sec007">
<title>Population under surveillance</title>
<p>The population under NISSS involves patients enrolled from the fourteen sentinel facilities in Kigoma, Dodoma, Mwanza, Manyara, Arusha, Mtwara, Dar es Salaam regions, and Zanzibar. These sentinel sites are Bombo regional hospital, Bububu hospital, Dodoma regional referral hospital (DRRH), Hydom Lutheran hospital, International School of Tanganyika Clinic center (IST Clinic), Istiqaama hospital, Kibondo district hospital, Mbalizi hospital, Meru district hospital, Mt. Meru regional referral hospital, Mwananyamala regional referral hospital (MRRH), Mzinga hospital, Sekou-Toure regional referral hospital and St. Benedict’s Ndanda hospital (SBNH).</p>
</sec>
<sec id="sec008">
<title>Inclusion criteria</title>
<p>The data of all influenza suspects detected by either Influenza-like illness (ILI) or Severe acute respiratory infections (SARI) case definition enrolled in the surveillance system and therefore included in the 2019 influenza data set (electronic forms) were used for analysis. We defined an <italic>ILI case</italic> as " a person with an acute respiratory infection with the measured fever of ≥ 38 C° and cough, with onset within the last ten days". <italic>SARI case was defined as</italic> "a person with an acute respiratory infection with a history of fever or measured fever of ≥ 38 C°, and cough; with onset within the last ten days, and requires hospitalization" [<xref ref-type="bibr" rid="pone.0283043.ref003">3</xref>].</p>
</sec>
<sec id="sec009">
<title>Exclusion criteria</title>
<p>We excluded patients whose data were missing important information such as age, case definition type, name of sentinel site, and influenza results. In addition, stakeholders who were unwilling to participate in the interview were not involved in this study.</p>
</sec>
<sec id="sec010">
<title>Study area</title>
<p>We evaluated the MoH epidemiology section in Dodoma, NPHL in Dar Es Salaam, and three selected sentinel sites: SBNH in the Mtwara region, DRRH in the Dodoma region, and MRRH in the Dar es salaam region. The sites were selected purposely due to location, different levels of care, and relatively higher number of patients enrolled in the NISSS in Tanzania compared to other sentinel sites.</p>
</sec>
<sec id="sec011">
<title>Specimen collection and laboratory procedures</title>
<p>The biospecimens used in the NISSS were nasopharyngeal and oropharyngeal swabs. A nasopharyngeal and an oropharyngeal swab sample for all patients who met the case definition (ILI/SARI) were collected from each sentinel site. In the sites, both swabs were placed into a single cryovial containing a viral transport medium. Cryovials containing specimens were immediately refrigerated and transported to the NIC in Dar Es Salaam via courier services. Upon receipt of specimens at NIC, the specimens were immediately stored at -80°C freezer before testing. The data for all samples received at NIC were entered into the Laboratory information system. Samples were tested for influenza A and influenza B viruses by real-time reverse-transcription polymerase chain reaction (rRT-PCR), using the CDC protocol for detection and characterization of seasonal influenza virus and 2009 pandemic influenza A virus subtype H1N1pdm09) as well as the WHO manual for the laboratory diagnosis and virological surveillance of influenza [<xref ref-type="bibr" rid="pone.0283043.ref004">4</xref>]. The RNA extraction from 140-μl aliquots of each specimen was performed using a QIamp viral RNA Minikit (Qiagen, Germany) according to the manufacturer’s instructions. A one-step rRT-PCR was performed using the AgPath kit (Applied Biosystems, Carlsbad. CA). Appropriate negative and positive control specimens were run alongside each reaction. The results were recorded as cycle threshold (CT) values. When controls met stated requirements, any influenza A or B virus results with a CT value of ≤ 39.9 as positive were recorded, and those with a CT reading of ≥40 were recorded as negative [<xref ref-type="bibr" rid="pone.0283043.ref005">5</xref>]. All specimens positive for influenza A virus were subtyped for seasonal H1, H3, and H1N1 pdm09, using rRT-PCR. Specimens positive for influenza A virus by rRT-PCR but not sub-typable were sent to the WHO influenza collaborating center for further antigenic characterization.</p>
</sec>
<sec id="sec012">
<title>Data collection procedure and surveillance evaluation techniques</title>
<p>Data on ILI and SARI from all fourteen sentinel facilities in Tanzania were extracted and abstracted from the NIC database (Disa*Lab) into Microsoft (MS) Excel<sup>®</sup> version 2019 format. Additionally, we selected three sentinel sites based on their location (southern, eastern, and central parts of the country), the volume of patients enrolled, and the different levels of care they provided (primary to tertiary hospital), and obtained permission for site visits.</p>
<p>The researchers interviewed all personnel directly involved in National Influenza Sentinel surveillance and also partook in surveillance activities in each of the selected sentinel sites while observing practices. The staff members were interviewed using a structured questionnaire and guided interviews on their knowledge of surveillance activities (see <xref ref-type="supplementary-material" rid="pone.0283043.s002">S1 File</xref>). We used the tally method to capture data on the completeness of case-based forms of influenza at NIC. We evaluated the surveillance system’s attributes using CDC guidelines for evaluating public health surveillance systems (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). We used the unique serial numbers on case investigation forms for each sentinel site to retrieve the randomized forms for examination. In addition, we collected and reviewed Influenza surveillance registers at the sentinel sites visited.</p>
<p>The system’s attributes evaluated include usefulness, simplicity, flexibility, representativeness, timeliness, data quality, acceptability, sensitivity, predictive value positive, and stability of the NISSS. We evaluated these attributes as follows:</p>
<p><italic>The usefulness of the surveillance system</italic> entails describing how the system provides information that is useful for public health authorities and communities (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). We assessed the usefulness of the Influenza surveillance system among the stakeholders from all selected sentinel sites through questionnaires and observation methods. The stakeholders provided the use status of the NISSS, and we assessed the utilization of the data through observation of the daily operations. In evaluating this attribute, the periodic reports and bulletin, case definition (SARI, ILI), interview guide and questionnaires, and case- registers were used to obtain this information. We observed the proportion of surveillance staff that reported that they regularly receive the monthly influenza bulletin, availability of annual influenza reports, identification and sharing of circulating seasonal influenza strains, and the outbreaks detected over the pre-established threshold. <italic>The simplicity of the surveillance system</italic> refers to both structure and ease of operation of a public health surveillance system (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). We assessed the simplicity of the NISSS through questionnaires and observation. We assessed the proportion of samples collected from admitted SARI cases at the sentinel sites as part of the NISSS operations.</p>
<p>Furthermore, in assessing this attribute, we observed the data collection methods and shipment and stakeholders’ perceptions of the NISSS operations using the structured questionnaire.</p>
<p><italic>The surveillance system’s flexibility is the ability</italic> to change information needs or operating conditions with little additional time, personnel, or allocated funds (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). We assessed the flexibility of NISSS through observation and review of reports and charts used by surveillance stakeholders. We also assessed the changes in standard case definition with time, new illnesses revealed, and the ability to include or detect other viral respiratory pathogens surveyed in NISSS. <italic>Representativeness of the surveillance system</italic> is the occurrence of a health-related event over time and its distribution in the population by place and person (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). In this evaluation, we assessed the representativeness of the NISSS through a review of periodic reports produced and the NISSS protocol in Tanzania. We checked the reports on the distribution of cases in all age categories and the selection criteria of the sentinel sites and geographical coverage.</p>
<p><italic>The timeliness of the surveillance system</italic> reflects the speed between steps in a public health surveillance system (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). The timeliness of the NISSS relates to the Turnaround Time (TAT) of the laboratory reports. TAT refers to the time elapsed from receiving samples in the Laboratory to releasing results (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). We assessed the timeliness of NISSS through a review of the TAT of laboratory reports since this can impact the timeliness of all operations of the entire system. We obtained the proportion of the timely reports released within pre-established TAT (7 days). <italic>Data quality of the surveillance system</italic> refers to the completeness and validity of the data recorded in the public health surveillance system (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). In evaluating this attribute, we assessed the completeness of the reports and case-based forms’ accuracy and consistency of data yielded from the NISSS. In assessing the completeness of NISSS, we obtained the proportion of complete filled reports and case forms. We obtained data accuracy information through the assessment of laboratory quality assurance protocol (internal quality control and external quality assessments). Furthermore, we evaluated data consistency by comparing the data of the same patients between sentinel sites and NIC in real time.</p>
<p><italic>Acceptability of the surveillance system</italic> is the willingness of persons and organizations to participate in the surveillance system (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). In assessing this attribute, we interviewed the stakeholders at the sentinel sites, NIC, MoH, and collaborating partners (WHO and CDC) of the NISSS in Tanzania. In addition, we observed the general performance of other attributes. <italic>The sensitivity of the surveillance system</italic> (at the level of outbreak detection) is the ability of the surveillance system to detect an outbreak. In evaluating the sensitivity of the NISSS, we observed the reports and bulletin to see the number of cases obtained against the pre-established threshold in the NISSS protocol in Tanzania. We obtained the proportion of the outbreaks detected against the target.</p>
<p><italic>The predictive value Positive (PVP)</italic> of the surveillance system refers to the proportion of reported cases with the health-related event under surveillance (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). We performed the PVP calculation using a formula: True positive/ (True positive + False negative). The "True positive" of the surveillance system are those patients who met the standard case definition of either SARI or ILI, depending on their clinical presentations, and therefore enrolled in the surveillance system, and their PCR results showed positive results of the influenza Virus A or Influenza Virus B. However, the other category of "False positive" of the surveillance system is those patients who met the standard case definitions (SARI/ILI) and enrolled in the surveillance system, but their PCR results showed no detection of the Influenza virus.</p>
<p><italic>The stability of the surveillance system</italic> is the reliability and availability of the public health surveillance system (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>). In assessing the stability of the NISSS, we interviewed the stakeholders and reviewed the system protocol to observe the funding mechanism of the NISSS including the number of internal and external funding sources.</p>
<p>We measured the performance of the NISSS using a scale from 1 to 5 to provide a score for each indicator with a percentage value from [0–20% [score 1 (very poor performance); [20–40% [score 2 (poor performance); [40–60% [score 3 (moderate performance); [60–80% [score 4 (good performance); [80–100% [score 5 (excellent performance). These scores are based on the consensus opinions of surveillance experts: virologists, public health specialists, and epidemiologists working at the NISSS.</p>
</sec>
<sec id="sec013">
<title>Data processing and analysis</title>
<p>Data were entered, cleaned, and stored in Microsoft (MS) Excel<sup>®</sup> version 2019, and we analyzed the system attributes using Microsoft Excel<sup>®</sup> and Stata<sup>®</sup> version 15.1. We calculated the frequency and proportions to evaluate the system attributes using predefined indicators described in the NISSS protocol (see <xref ref-type="supplementary-material" rid="pone.0283043.s003">S2 File</xref>).</p>
</sec>
<sec id="sec014">
<title>Ethics statement</title>
<p>We evaluated the NISSS within the framework of the Integrated Disease Surveillance and Response matrix implemented by the Tanzania MoH and therefore did not require a formal review by Ethical Review Committees. This study did not involve direct contact with the patients; we based it on the verbal consent obtained from patients before enrolment into the surveillance. We sought and obtained permission from the MoH of Tanzania for the epidemiology section and authorities in the sentinel facilities prior to the commencement of the evaluation process. We anonymized the data before being analyzed to ensure patient confidentiality.</p>
</sec>
</sec>
<sec id="sec015" sec-type="results">
<title>Results</title>
<sec id="sec016">
<title>Characteristics of the study participants</title>
<p>The Influenza Laboratory electronic forms from the Laboratory information system (Disa*Lab) at NIC showed that; a total of 1731 nasopharyngeal and oropharyngeal swabs specimens from suspected cases of influenza were collected from January to December 2019, of which 912 (52.7%) were from male participants. The individuals in the surveillance system had a median age of 3 years (Interquartile range (IQR) = 0–28). Forty-one percent (708/1731) of patients were enrolled using the SARI case definition type in the surveillance system. Eight percent (83/1023) of patients who presented with ILI symptoms were confirmed positive for influenza B virus, and only 0.85% (6/708) of these presented with SARI symptoms during the time of enrolment (see <xref ref-type="table" rid="pone.0283043.t001">Table 1</xref> and <xref ref-type="fig" rid="pone.0283043.g001">Fig 1</xref>). Of all samples from ILI cases, 21.5% (373/1731) were laboratory-confirmed influenza cases. Most samples were collected from MRRH [25.8% (447/1731)], and the least number of samples were from Bombo regional hospital [0.1% (2/1731)]. Most laboratory results of patients under surveillance [63.4% (1098/1731)] did not meet the required turnaround time (TAT) of ≤7 days for ≥90% of all patient results (see <xref ref-type="table" rid="pone.0283043.t001">Table 1</xref>). The TAT of the patients’ results captured was less than 50% of the target in most sentinel sites, regardless of their distance from the NIC (see Fig 4).</p>
<fig id="pone.0283043.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Distribution of influenza types in Tanzania according to case definition used among confirmed cases of influenza from January to December 2019 (N = 373).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0283043.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.t001</object-id>
<label>Table 1</label> <caption><title>Socio-demographic characteristics of the people under the National Influenza Sentinel Surveillance System in Tanzania, 2019.</title></caption>
<alternatives>
<graphic id="pone.0283043.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="left" colspan="3">Case definition type</th>
</tr>
<tr>
<th align="left">Age (years)</th>
<th align="left">ILI (n = 1023)</th>
<th align="left">SARI (n = 708)</th>
<th align="left">Total (N = 1731)</th>
</tr>
<tr>
<th align="left"/>
<th align="left">n (%)</th>
<th align="left">n (%)</th>
<th align="left">n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"> 0–4</td>
<td align="left">384 (37.54)</td>
<td align="left">569 (80.37)</td>
<td align="left">953 (55.05)</td>
</tr>
<tr>
<td align="left"> 5–14</td>
<td align="left">101 (9.87)</td>
<td align="left">27 (3.81)</td>
<td align="left">128 (7.39)</td>
</tr>
<tr>
<td align="left"> 15–24</td>
<td align="left">137 (13.39)</td>
<td align="left">23 (3.25)</td>
<td align="left">160 (9.24)</td>
</tr>
<tr>
<td align="left"> 25–34</td>
<td align="left">174 (17.01)</td>
<td align="left">18 (2.54)</td>
<td align="left">192 (11.09)</td>
</tr>
<tr>
<td align="left"> 35–44</td>
<td align="left">98 (9.58)</td>
<td align="left">18 (2.54)</td>
<td align="left">116 (6.70)</td>
</tr>
<tr>
<td align="left"> 45–54</td>
<td align="left">47 (4.59)</td>
<td align="left">14 (1.98)</td>
<td align="left">61 (3.52)</td>
</tr>
<tr>
<td align="left"> 55–64</td>
<td align="left">53 (5.18)</td>
<td align="left">15 (2.12)</td>
<td align="left">68 (3.93)</td>
</tr>
<tr>
<td align="left"> ≥65</td>
<td align="left">29 (2.83)</td>
<td align="left">24 (3.39)</td>
<td align="left">53 (3.06)</td>
</tr>
<tr>
<td align="left">Median (IQR)</td>
<td align="left">18 (2–33)</td>
<td align="left">1 (0–3)</td>
<td align="left">3 (0–28)</td>
</tr>
<tr>
<td align="left" colspan="4"><bold>Sex</bold></td>
</tr>
<tr>
<td align="left"> Female</td>
<td align="left">531 (51.91)</td>
<td align="left">276 (38.98)</td>
<td align="left">807 (46.62)</td>
</tr>
<tr>
<td align="left"> Male</td>
<td align="left">481 (47.02)</td>
<td align="left">431 (60.88)</td>
<td align="left">912 (52.69)</td>
</tr>
<tr>
<td align="left"> Missing</td>
<td align="left">11 (1.08)</td>
<td align="left">1 (0.14)</td>
<td align="left">12 (0.69)</td>
</tr>
<tr>
<td align="left" colspan="4"><bold>Sentinel site</bold></td>
</tr>
<tr>
<td align="left"> Bombo regional hospital</td>
<td align="left">2 (0.20)</td>
<td align="left">0 (0.00)</td>
<td align="left">2 (0.12)</td>
</tr>
<tr>
<td align="left"> Bububu hospital</td>
<td align="left">184 (17.99)</td>
<td align="left">0 (0.00)</td>
<td align="left">184 (10.63)</td>
</tr>
<tr>
<td align="left"> Dodoma regional referral hospital</td>
<td align="left">6 (0.59)</td>
<td align="left">50 (7.06)</td>
<td align="left">56 (3.24)</td>
</tr>
<tr>
<td align="left"> Hydom Lutheran hospital</td>
<td align="left">47 (4.59)</td>
<td align="left">38 (5.37)</td>
<td align="left">85 (4.91)</td>
</tr>
<tr>
<td align="left"> International School of Tanganyika Clinic</td>
<td align="left">39 (3.81)</td>
<td align="left">0 (0.00)</td>
<td align="left">39 (2.25)</td>
</tr>
<tr>
<td align="left"> Istiqaama hospital</td>
<td align="left">5 (0.49)</td>
<td align="left">0 (0.00)</td>
<td align="left">5 (0.29)</td>
</tr>
<tr>
<td align="left"> Kibondo district hospital</td>
<td align="left">24 (2.35)</td>
<td align="left">100 (14.12)</td>
<td align="left">124 (7.16)</td>
</tr>
<tr>
<td align="left"> Mbalizi hospital</td>
<td align="left">193 (18.87)</td>
<td align="left">0 (0.00)</td>
<td align="left">193 (11.15)</td>
</tr>
<tr>
<td align="left"> Meru district hospital</td>
<td align="left">97 (9.48)</td>
<td align="left">41 (5.79)</td>
<td align="left">138 (7.97)</td>
</tr>
<tr>
<td align="left"> Mt. Meru regional referral hospital</td>
<td align="left">64 (6.26)</td>
<td align="left">99 (13.98)</td>
<td align="left">163 (9.42)</td>
</tr>
<tr>
<td align="left"> Mwananyamala regional referral hospital</td>
<td align="left">170 (16.62)</td>
<td align="left">277 (39.12)</td>
<td align="left">447 (25.82)</td>
</tr>
<tr>
<td align="left"> Mzinga hospital</td>
<td align="left">65 (6.35)</td>
<td align="left">0 (0.00)</td>
<td align="left">65 (3.76)</td>
</tr>
<tr>
<td align="left"> Sekou-Touré regional referral hospital</td>
<td align="left">43 (4.20)</td>
<td align="left">27 (3.81)</td>
<td align="left">70 (4.04)</td>
</tr>
<tr>
<td align="left"> St. Benedict’s Ndanda hospital</td>
<td align="left">84 (8.21)</td>
<td align="left">76 (10.73)</td>
<td align="left">160 (9.24)</td>
</tr>
<tr>
<td align="left" colspan="4"><bold>Influenza virus results (rRT-PCR)</bold></td>
</tr>
<tr>
<td align="left"> Influenza A Detected</td>
<td align="left">175 (17.11)</td>
<td align="left">109 (15.40)</td>
<td align="left">284 (16.41)</td>
</tr>
<tr>
<td align="left">  A(H3N2)</td>
<td align="left">31 (3.03)</td>
<td align="left">23 (3.25)</td>
<td align="left">54 (3.12)</td>
</tr>
<tr>
<td align="left">  A(Unclassified)</td>
<td align="left">144 (14.08)</td>
<td align="left">86 (12.15)</td>
<td align="left">230 (13.29)</td>
</tr>
<tr>
<td align="left"> Influenza B Detected</td>
<td align="left">83 (8.11)</td>
<td align="left">6 (0.85)</td>
<td align="left">89 (5.14)</td>
</tr>
<tr>
<td align="left"> Influenza A and B Not Detected</td>
<td align="left">757 (74.00)</td>
<td align="left">591 (83.47)</td>
<td align="left">1348 (77.87)</td>
</tr>
<tr>
<td align="left"> Failed samples</td>
<td align="left">8 (80.00)</td>
<td align="left">2 (0.28)</td>
<td align="left">10 (0.58)</td>
</tr>
<tr>
<td align="left" colspan="4"><bold>Turnaround time (TAT)</bold></td>
</tr>
<tr>
<td align="left"> ≤ 7 days</td>
<td align="left">302 (29.52)</td>
<td align="left">331 (46.75)</td>
<td align="left">633 (36.57)</td>
</tr>
<tr>
<td align="left"> &gt;7 days</td>
<td align="left">721 (70.48)</td>
<td align="left">377 (53.25)</td>
<td align="left">1098 (63.43)</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec017">
<title>Usefulness (Utility) of influenza surveillance system</title>
<p>We assessed the usefulness of the Influenza surveillance system among the stakeholders from all selected sentinel sites, and 80% (10/12) agreed on the importance of NISSS in Tanzania. Furthermore, the surveillance system provided valuable data to all stakeholders via periodic reports, including weekly, monthly and annual influenza surveillance bulletins. Additionally, national surveillance data allowed the calculation of the disease burden and showed the weekly distribution of influenza cases in the country (see <xref ref-type="fig" rid="pone.0283043.g002">Fig 2</xref>). The mean score for the utility was 5 (see Table 3).</p>
<fig id="pone.0283043.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Weekly distribution of influenza cases in Tanzania from January to December 2019 (N = 373).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec018">
<title>Simplicity</title>
<p>Only 21.4% (600/2803) of all patients admitted to sentinel sites (SBNH, DRRH, and MRRH) enrolled by SARI standard case definition their oropharyngeal and nasopharyngeal samples were collected for laboratory testing (see <xref ref-type="table" rid="pone.0283043.t002">Table 2</xref>). Furthermore, we also observed the use of manual registers at the sentinel sites, which may have influenced the delay of surveillance activities, compromising the data accuracy. These data from selected sites show that the surveillance system is complex due to its data collection method. The mean score for simplicity was 3 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
<table-wrap id="pone.0283043.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.t002</object-id>
<label>Table 2</label> <caption><title>The distribution of the SARI patients under the National Influenza Sentinel Surveillance System and the average samples collected per study sentinel sites in Tanzania, 2019.</title></caption>
<alternatives>
<graphic id="pone.0283043.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="5">Sentinel site</th>
</tr>
<tr>
<th align="left"/>
<th align="left">SBNH</th>
<th align="left">DRRH</th>
<th align="left">MRRH</th>
<th align="left">Total</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>P1</bold></td>
<td align="left">1186</td>
<td align="left">79</td>
<td align="left">1538</td>
<td align="left">2803</td>
</tr>
<tr>
<td align="left"><bold>ST</bold></td>
<td align="left">122 (10%)</td>
<td align="left">79 (100%)</td>
<td align="left">399(26%)</td>
<td align="left">600 (21%)</td>
</tr>
<tr>
<td align="left"><bold>AC</bold></td>
<td align="left">10 (13%)</td>
<td align="left">7 (9%)</td>
<td align="left">33 (41%)</td>
<td align="left">50 (63%)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><bold>Key: P1:</bold> Admitted patients who fulfilled the influenza case definition for SARI; <bold>ST</bold>: Total number of samples from SARI admitted patients from January to December 2019; <bold>AC</bold>: Average target set for a sample collection from January to December 2019 per month (80 samples per month).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0283043.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.t003</object-id>
<label>Table 3</label> <caption><title>Findings from the evaluation of the National Influenza Sentinel Surveillance System in Tanzania,2019.</title></caption>
<alternatives>
<graphic id="pone.0283043.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" style="background-color:#F2F2F2">System attribute</th>
<th align="center" style="background-color:#F2F2F2">Indicators</th>
<th align="left" style="background-color:#F2F2F2">Score (%)</th>
<th align="center" style="background-color:#F2F2F2">Mean score (%)</th>
<th align="center" style="background-color:#F2F2F2">Target score (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="6"><bold>Utility/Usefulness</bold></td>
<td align="left">Importance of the surveillance system</td>
<td align="left">5 (80)</td>
<td align="left" rowspan="6">5 (92)</td>
<td align="left" rowspan="6">5 (≥80)</td>
</tr>
<tr>
<td align="left">Provided useful data</td>
<td align="left">5 (90)</td>
</tr>
<tr>
<td align="left">The proportion of surveillance staff that reported that they regularly receive the monthly Influenza bulletin</td>
<td align="left">5 (100)</td>
</tr>
<tr>
<td align="left">Annual Influenza report</td>
<td align="left">5 (100)</td>
</tr>
<tr>
<td align="left">Identification and sharing of circulating seasonal influenza strains</td>
<td align="left">5 (80)</td>
</tr>
<tr>
<td align="left">Outbreaks detected over the pre-established threshold</td>
<td align="left">5 (100)</td>
</tr>
<tr>
<td align="left" rowspan="3"><bold>Simplicity</bold></td>
<td align="left">The proportion of samples collected from admitted SARI patients [N: Number of samples collected from admitted SARI patients; D: Total number of patients that met SARI case definition]</td>
<td align="left">2 (21)</td>
<td align="left">3 (57)</td>
<td align="left">5 (≥80)</td>
</tr>
<tr>
<td align="left">Data collection and shipment</td>
<td align="left">3 (50)</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Perception of stakeholders on the simplicity of the system</td>
<td align="left">5 (100)</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left" rowspan="3"><bold>Flexibility</bold></td>
<td align="left">Changes in standard case definition</td>
<td align="left">5 (100)</td>
<td align="left">5 (100)</td>
<td align="left" rowspan="2">5 (≥80)</td>
</tr>
<tr>
<td align="left">New illnesses revealed by the system</td>
<td align="left">5 (100)</td>
<td align="left">5 (100)</td>
</tr>
<tr>
<td align="left">Inclusion of other viral respiratory pathogens surveyed with the influenza surveillance system</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left" rowspan="4"><bold>Representativeness</bold></td>
<td align="left">The total number of patients captured</td>
<td align="left">3 (50)</td>
<td align="left" rowspan="4">4 (64)</td>
<td align="left" rowspan="4">5 (≥80)</td>
</tr>
<tr>
<td align="left">Number of sentinel sites involved</td>
<td align="left">4 (60)</td>
</tr>
<tr>
<td align="left">Geographical coverage of the sentinel sites</td>
<td align="left">3 (44)</td>
</tr>
<tr>
<td align="left">Inclusion of all age groups in NISSS</td>
<td align="left">5 (100)</td>
</tr>
<tr>
<td align="left"><bold>Timeliness</bold></td>
<td align="left">The proportion of timely reporting of results <bold>[N:</bold> Number of results reported within required TAT (within 1 week); D: Total number of results reported at a time period].</td>
<td align="left">3 (55)</td>
<td align="left">3 (55)</td>
<td align="left">5 (≥90)</td>
</tr>
<tr>
<td align="left"><bold>Data quality:</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left" rowspan="2"><bold>i. Completeness</bold></td>
<td align="left">Percentage of blank forms <bold>[N:</bold> Number of incomplete filled forms; <bold>D:</bold> Total Number of evaluated forms]</td>
<td align="left">3 (40)</td>
<td align="left">3 (40)</td>
<td align="left">1 (&lt;10)</td>
</tr>
<tr>
<td align="left">Percentage of complete filled case-based forms/ reports [<bold>N:</bold> Number of complete filled forms: Total number of evaluated forms case-based forms and/or periodic reports].</td>
<td align="left">3 (60)</td>
<td align="left">3 (60)</td>
<td align="left">5 (≥90)</td>
</tr>
<tr>
<td align="left" rowspan="2"><bold>ii. Data accuracy</bold></td>
<td align="left">% EQA performance <bold>[N:</bold> Number of EQA panels with performance ≥90%; <bold>D:</bold> Total number of EQA panels evaluated].</td>
<td align="left">5 (100)</td>
<td align="left">5 (100)</td>
<td align="left">5 (≥90)</td>
</tr>
<tr>
<td align="left">% Of IQC passed within a selected time period <bold>[N:</bold> Total number of IQC passed; D: Total number of IQC evaluated].</td>
<td align="left">5 (100)</td>
<td align="left">5 (100)</td>
<td align="left">5 (100)</td>
</tr>
<tr>
<td align="left"><bold>iii. Data consistency</bold></td>
<td align="left">% Consistency between samples sent from selected sentinel sites to NPHL to those received at NPHL [Proportion of the difference in the number of samples sent from sentinel sites to NPHL to the number of the same samples received at NPHL]</td>
<td align="left">4 (77)</td>
<td align="left">4 (77)</td>
<td align="left">5 (≥95)</td>
</tr>
<tr>
<td align="left" rowspan="2"><bold>Acceptability</bold></td>
<td align="left">Performance observation from other attributes</td>
<td align="left">3 (50)</td>
<td align="left">4 (75)</td>
<td align="left">5 (≥95)</td>
</tr>
<tr>
<td align="left">Perception of stakeholders on accepting the system [<bold>N:</bold> Number of stakeholders accepting the system; D: Total number of stakeholders evaluated via interview].</td>
<td align="left">5 (100)</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left"><bold>Sensitivity</bold></td>
<td align="left">The proportion of the number of outbreaks identified by the system [<bold>N:</bold> Number of outbreaks detected by the system; <bold>D:</bold> Total number of outbreaks that occurred in a time period].</td>
<td align="left">5 (100)</td>
<td align="left">5 (100)</td>
<td align="left">5 (≥90)</td>
</tr>
<tr>
<td align="left"><bold>Predictive value Positive (PVP)</bold></td>
<td align="left">The proportion of cases correctly picked by the surveillance system (TP); the number of healthy individuals picked as cases by the system (FP). [<bold>N:</bold> Number of patients truly identified by the system (TP); D: Total number of patients identified by the surveillance system (TP+FP)].</td>
<td align="left">2 (21)</td>
<td align="left">2 (21)</td>
<td align="left">5 (≥90)</td>
</tr>
<tr>
<td align="left"><bold>Stability</bold></td>
<td align="left">The number of funding sources of the system presence of internal and/or external funding mechanisms.</td>
<td align="left">4 (80)</td>
<td align="left">4 (80)</td>
<td align="left">5 (≥80)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p><bold>Key:</bold> Surveillance performance description: a scale from 1 to 5 was used to provide a score for each indicator with a percentage value as follows:</p></fn>
<fn id="t003fn002"><p>[0–20% [score 1 (very poor performance); [20–40% [score 2 (poor performance); [40–60% [score 3 (moderate performance); [60–80% [score 4 (good performance); [80–100% [score 5 (excellent performance). (N: Numerator, D: Denominator).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec019">
<title>Data quality</title>
<p>In this attribute, we examined the data completeness, accuracy, and data consistency, and the results were as follows:</p>
</sec>
<sec id="sec020">
<title>Data consistency</title>
<p>The overall data consistency between sentinel sites and NPHL was 77% (663/861). We observed the highest discrepancy in samples sent from MRRH to NPHL with a standard deviation of 29.0 (see <xref ref-type="supplementary-material" rid="pone.0283043.s004">S3 File</xref>). The mean score for data consistency was 4 (See <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec021">
<title>Data completeness</title>
<p>We observed that 60% (164/415) of the forms were incompletely filled. We saw that most of the blanks on these forms were in the case definition type (15%) as well as the date of sample collection (11%) fields (see <xref ref-type="fig" rid="pone.0283043.g003">Fig 3</xref>). The mean score for data completeness was 3 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
<fig id="pone.0283043.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.g003</object-id>
<label>Fig 3</label>
<caption>
<title>The proportion of incompleteness of selected parameters on influenza case-based forms used by the National Influenza Sentinel Surveillance System in Tanzania, 2019 (N = 415).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec022">
<title>Data accuracy</title>
<p>Through document review, we observed that; Internal Quality Control (IQC) was always done in each run of the samples and also passed External Quality Assessment (EQA) with 100% concordance with WHO standards. Furthermore, NPHL had an average performance of 100% in all EQA panels. The mean score for data accuracy was 5 (<xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec023">
<title>Flexibility</title>
<p>The system is flexible after standard case definitions were revised in 2019 to comply with WHO’s standards and prove to work through the system [<xref ref-type="bibr" rid="pone.0283043.ref009">9</xref>]. Also, the system, through influenza Laboratory testing protocol, allows the investigation of other viral respiratory infections apart from influenza. The mean score for flexibility was 5 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec024">
<title>Representativeness</title>
<p>Sentinel sites were selected representatively (not randomly) based on population density, climate, and socio-diversity to estimate the country’s disease burden. We captured data from the 14 sentinel sites found in eight regions of Tanzania. Furthermore, the distribution of people under surveillance involved all age groups (see <xref ref-type="table" rid="pone.0283043.t001">Table 1</xref>). The mean score for representativeness was 4 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec025">
<title>Timeliness</title>
<p>Among all patients’ samples tested for rRT-PCR influenza test, only 36.6% (633/1731) met the standard TAT (Target is ≥90%). Furthermore, 57.1% (8/14) of all sentinel sites had less than 50% (Target ≥90%) of patient samples met the standard TAT (see <xref ref-type="fig" rid="pone.0283043.g004">Fig 4</xref>). The mean score for timeliness was 3 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
<fig id="pone.0283043.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0283043.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Turnaround coverage among the sentinel sites of the National Influenza Sentinel Surveillance System (NISSS) in Tanzania, January to December 2019.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec026">
<title>Acceptability</title>
<p>The interviewed stakeholders accepted the operations of the NISSS by 100% (12/12). The mean score for acceptability of the NISSS was 4 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec027">
<title>Sensitivity</title>
<p>The NISSS could detect cases of influenza and could confirm several outbreaks of influenza in different regions of Tanzania. The mean score for the sensitivity of the NISSS was 5 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec028">
<title>Predictive value positive (PVP)</title>
<p>The number of patients enrolled in influenza surveillance who tested positive for influenza by rRT-PCR in 2019 was 373, and the number of those enrolled but had negative rRT-PCR results was 1348. Therefore, PVP was 21.7% (373/1721). The mean score for PVP of the NISSS was 2 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
<sec id="sec029">
<title>Stability</title>
<p>The system utilizes employed staff at all levels. The system is financially stable since WHO and the United States government fund it through the CDC and the MoH of Tanzania. The mean score for the stability of the NISSS was 4 (see <xref ref-type="table" rid="pone.0283043.t003">Table 3</xref>).</p>
</sec>
</sec>
<sec id="sec030" sec-type="conclusions">
<title>Discussion</title>
<p>This study assessed the NISSS in Tanzania to provide comprehensive data on strengths and weaknesses and provide suitable recommendations for improvement. The observed distribution of the influenza disease by sex, influenza type, and case definition type, from the NISSS in Tanzania, has not shown any significant difference from the study done by Mmbaga <italic>et al</italic>. in 2012 [<xref ref-type="bibr" rid="pone.0283043.ref004">4</xref>].</p>
<p>This evaluation has shown that the NISSS in Tanzania has moderate overall performance (with a mean score of 3 to 4). Although the PVP was low [21.7% (target ≥90%)], this is relatively higher compared to the PVP of 7.9% obtained from the previous evaluation report on 30 months of evaluation after the establishment of the NISSS in Tanzania [<xref ref-type="bibr" rid="pone.0283043.ref004">4</xref>]. The observed inconsistency of data from the sentinel sites to the National Influenza Laboratory (that is, 23% data discrepancy compared with the target of &lt;5%) is most likely due to errors during documentation at the sentinel sites.</p>
<p>The observed higher TAT [only 37% (target ≥90%)] is likely due to prolonged registration time at NPHL, which may be due to a shortage of human resources, which could hasten the registration process of case-based forms in LIS before testing. Although all sentinel sites did not meet the target TAT, their distance from NIC may have contributed to the delay of patients’ results, and thus, we suggest further investigation that will address the TAT captured in every sentinel site and their distance from NIC. The timeliness of the NISSS in Tanzania may have been affected by the geographical distribution of sentinel sites and the simplicity of data collection and reporting methods.</p>
<p>An electronic information management system (from the sentinel sites level to the NIC) was one of the most critical recommendations proposed by surveillance staff to improve data completeness, quality monitoring, and timeliness. The electronic system would facilitate real-time data sharing at all levels involved in the NISSS [<xref ref-type="bibr" rid="pone.0283043.ref010">10</xref>]. The evaluation of the syndromic influenza sentinel surveillance system in Madagascar between 2009 and 2014 showed that by using mobile phones and texting for the transmission of daily aggregated data, the simplicity of the system was strengthened, improving the completeness, quality and timeliness of the data as well as acceptability of the system to the sentinel site staff [<xref ref-type="bibr" rid="pone.0283043.ref011">11</xref>]. This is in line with the recommendation that a revised data management approach, which offers the advantage of automation and a user-friendly interface between the sentinel sites and the NIC, would ultimately improve the acceptance and utility of the surveillance system.</p>
<p>Although system representativeness was moderate (64%) due to the involvement of all age categories in the surveillance, the number of sentinel sites are still inadequate (only 14 sentinel sites available) to cover the entire population of Tanzania and thus, increasing more sentinel sites would have increased the coverage and the level of system representativeness. Having a lower PVP suggests the need for the National Influenza Technical Working Group (NITWG) to plan for reviewing the current case definition to improve the PVP and thus ensure that the NISSS enrolls the actual cases of Influenza to minimize misuse of the surveillance resources.</p>
<p>In this evaluation, we report that; the prevalence of Influenza A (with circulating Influenza A subtype, H3N2) is relatively higher than that of influenza B regardless of the case definition type used, sex, or age category of the individuals under surveillance. Several previous studies have shown similar results from evaluating influenza surveillance [<xref ref-type="bibr" rid="pone.0283043.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0283043.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0283043.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0283043.ref009">9</xref>]. This suggests the need for routine further characterization of the Influenza A virus detected to identify any new strain capable of causing a pandemic.</p>
<p>From a virologic perspective, the surveillance of Influenza in 2019 permitted the characterization of circulating influenza viruses. It ensured strong links with the WHO Collaborating Centers on Influenza by participating in vaccine strain selection and shipping specimens twice a year, as recommended by WHO. Although the NISSS is currently stable due to the external funding mechanism, this suggests the need to deploy internal funding mechanisms to provide support to the MoH, NIC, and sentinel sites. Subsequently, this will create a sense of ownership of the system among the stakeholders and enable the consistently good performance of the NISSS in Tanzania.</p>
</sec>
<sec id="sec031" sec-type="conclusions">
<title>Conclusion</title>
<p>The system performed overall satisfactorily in compliance with its objectives and generated accurate data with an average performance of 100%, which entails a realistic estimation of the burden of influenza disease in the country. As a result, it will assist the country in prioritizing responses to disease outbreaks and even planning for future vaccine development. The complexity of the system contributed to its data inconsistency. Better use of the available data could be made to inform and promote preventive measures, especially among the most vulnerable population (i.e., children aged &lt; 5 years). Increasing sentinel sites could be made to maximize coverage and level of system representativeness.</p>
<sec id="sec032">
<title>Limitations of the study</title>
<p>The sentinel sites used manual registers for the registration of surveillance individuals, while NIC uses an electronic system (Disa*Lab). Since these are two different systems, they may have contributed to the high data discrepancy between NIC and sentinel sites.</p>
</sec>
</sec>
<sec id="sec033" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="pone.0283043.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Data flow of the National Influenza Sentinel Surveillance System in Tanzania.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0283043.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s002" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>Data collection tool for the evaluation of the National Influenza Surveillance System in Tanzania.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0283043.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s003" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>Updated guidelines for evaluating public health surveillance systems.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0283043.s004" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s004" xlink:type="simple">
<label>S3 File</label>
<caption>
<title>Verification of the number of samples sent to NIC by using registers from sentinel sites and Laboratory information system (LIS).</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0283043.s005" mimetype="application/zip" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s005" xlink:type="simple">
<label>S4 File</label>
<caption>
<title>Data set for the ILI and SARI patients enrolled in the NISSS in Tanzania, 2019.</title>
<p>(ZIP)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>Sincere appreciation to the National Public Health Laboratory for technical support. The authors also wish to acknowledge the WHO-emergency preparedness and response, Dar es Salaam, Tanzania, as well as SBNH, DRRH, and MRRH, for their technical support during the data collection period.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0283043.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>WHO Global Influenza Programme Surveillance and Epidemiology team</collab>., “<article-title>Protocol for National Influenza Sentinel</article-title>,” <source><italic>Isbn</italic></source>, p. <fpage>2</fpage>, <year>2015</year>.</mixed-citation></ref>
<ref id="pone.0283043.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>WHO, “WHO | Influenza (Seasonal)</collab>,” <source><italic>Bulletin of the World Health Organization</italic></source>, <year>2013</year>.</mixed-citation></ref>
<ref id="pone.0283043.ref003"><label>3</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>, <source><italic>National Protocol for Influenza Sentinel Surveillance System</italic></source>, <edition designator="1">First edit</edition>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organisation, Geneva</publisher-name>, <year>2015</year>.</mixed-citation></ref>
<ref id="pone.0283043.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mmbaga</surname> <given-names>V. M.</given-names></name> <etal>et al</etal>., “<article-title>Results from the First 30 Months of National Sentinel Surveillance for Influenza in Tanzania, 2008–2010</article-title>,” <source><italic>J</italic>. <italic>Infect</italic>. <italic>Dis</italic>.</source>, vol. <volume>206</volume>, no. <issue>suppl_1</issue>, pp. <fpage>S80</fpage>–<lpage>S86</lpage>, <month>Dec</month>. <year>2012</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jis540" xlink:type="simple">10.1093/infdis/jis540</ext-link></comment> <object-id pub-id-type="pmid">23169977</object-id></mixed-citation></ref>
<ref id="pone.0283043.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Babakazo</surname> <given-names>P.</given-names></name> <etal>et al</etal>., “<article-title>Evaluation of the influenza sentinel surveillance system in the Democratic Republic of Congo, 2012–2015</article-title>,” <source><italic>BMC Public Health</italic></source>, vol. <volume>19</volume>, no. <issue>1</issue>, pp. <fpage>1</fpage>–<lpage>12</lpage>, <month>Dec</month>. <year>2019</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/S12889-019-8008-2" xlink:type="simple">10.1186/S12889-019-8008-2</ext-link></comment>/TABLES/5</mixed-citation></ref>
<ref id="pone.0283043.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Budgell</surname> <given-names>E.</given-names></name> <etal>et al</etal>., “<article-title>Evaluation of two influenza surveillance systems in South Africa</article-title>,” <source><italic>PLoS One</italic></source>, vol. <volume>10</volume>, no. <issue>3</issue>, <month>Mar</month>. <year>2015</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0120226" xlink:type="simple">10.1371/journal.pone.0120226</ext-link></comment> <object-id pub-id-type="pmid">25822719</object-id></mixed-citation></ref>
<ref id="pone.0283043.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nuvey</surname> <given-names>F. S.</given-names></name> <etal>et al</etal>., “<article-title>Evaluation of the sentinel surveillance system for influenza-like illnesses in the Greater Accra region, Ghana, 2018</article-title>,” <source><italic>PLoS One</italic></source>, vol. <volume>14</volume>, no. <issue>3</issue>, p. <fpage>e0213627</fpage>, <month>Mar</month>. <year>2019</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0213627" xlink:type="simple">10.1371/journal.pone.0213627</ext-link></comment> <object-id pub-id-type="pmid">30870489</object-id></mixed-citation></ref>
<ref id="pone.0283043.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yazidi</surname> <given-names>R.</given-names></name> <etal>et al</etal>., “<article-title>Evaluation of the influenza-like illness surveillance system in Tunisia, 2012–2015</article-title>,” <source><italic>BMC Public Health</italic></source>, vol. <volume>19</volume>, no. <issue>1</issue>, pp. <fpage>1</fpage>–<lpage>9</lpage>, <month>Jun</month>. <year>2019</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/S12889-019-7035-3" xlink:type="simple">10.1186/S12889-019-7035-3</ext-link></comment>/FIGURES/2</mixed-citation></ref>
<ref id="pone.0283043.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adogu</surname> <given-names>P. O.</given-names></name>, <name name-style="western"><surname>Achebe</surname> <given-names>C. I.</given-names></name>, and <name name-style="western"><surname>Ubajaka</surname> <given-names>C. F.</given-names></name>, “<article-title>Epidemiologic study of influenza infection in a developing country-experience in a tertiary care center in South East Nigeria</article-title>,” <source><italic>J</italic>. <italic>Med</italic>. <italic>Med</italic>. <italic>Sci</italic>.</source>, vol. <volume>5</volume>, no. <issue>3</issue>, pp. <fpage>61</fpage>–<lpage>70</lpage>, <year>2014</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14303/jmms.2014.040" xlink:type="simple">10.14303/jmms.2014.040</ext-link></comment></mixed-citation></ref>
<ref id="pone.0283043.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sosin</surname> <given-names>D. M.</given-names></name>, “<article-title>Draft framework for evaluating syndromic surveillance systems</article-title>,” <source><italic>J</italic>. <italic>Urban Health</italic></source>, vol. <volume>80</volume>, no. <issue>2</issue> Suppl 1, <year>2003</year>, <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/pl00022309" xlink:type="simple">10.1007/pl00022309</ext-link></comment> <object-id pub-id-type="pmid">12791773</object-id></mixed-citation></ref>
<ref id="pone.0283043.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rakotoarisoa</surname> <given-names>A.</given-names></name> <etal>et al</etal>., “<article-title>Lessons from the field Evaluation of the influenza sentinel surveillance system in Madagascar</article-title>,” <source><italic>Bull World Heal</italic>. <italic>Organ</italic></source>, vol. <volume>95</volume>, pp. <fpage>375</fpage>–<lpage>381</lpage>, <year>2017</year>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0283043.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Meseko</surname>
<given-names>Clement Adebajo</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>Clement Adebajo Meseko</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0283043" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">4 Aug 2022</named-content>
</p>
<p><!-- <div> -->PONE-D-22-16315<!-- </div> --><!-- <div> -->Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019<!-- </div> --><!-- <div> -->PLOS ONE</p>
<p>Dear Dr. Shedura,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.<!-- </div> --></p>
<p>Please pay particular attention to the structural and textual points raised by the reviewers </p>
<p>Please submit your revised manuscript by Sep 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Clement Adebajo Meseko, DVM, PhD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal Requirements:</p>
<p>When submitting your revision, we need you to address these additional requirements.</p>
<p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at </p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and </p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>.</p>
<p>2. Please amend your current ethics statement to address the following concerns:</p>
<p>a) Did participants provide their written or verbal informed consent to participate in this study?</p>
<p>b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure.</p>
<p>3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. " xlink:type="simple">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. </ext-link></p>
<p>In your revised cover letter, please address the following prompts:</p>
<p>a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.</p>
<p>b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <ext-link ext-link-type="uri" xlink:href="http://www.bmj.com/content/340/bmj.c181.long" xlink:type="simple">http://www.bmj.com/content/340/bmj.c181.long</ext-link> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories" xlink:type="simple">http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories</ext-link>.</p>
<p>We will update your Data Availability statement on your behalf to reflect the information you provide.</p>
<p>4. We note that Figure 1 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/licenses-and-copyright" xlink:type="simple">http://journals.plos.org/plosone/s/licenses-and-copyright</ext-link>.</p>
<p>We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:</p>
<p>a) You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  </p>
<p>We recommend that you contact the original copyright holder with the Content Permission Form (<ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf" xlink:type="simple">http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf</ext-link>) and the following text:</p>
<p>“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">http://creativecommons.org/licenses/by/4.0/</ext-link>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”</p>
<p>Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.</p>
<p>In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”</p>
<p>b) If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.</p>
<p>The following resources for replacing copyrighted map figures may be helpful:</p>
<p>USGS National Map Viewer (public domain): <ext-link ext-link-type="uri" xlink:href="http://viewer.nationalmap.gov/viewer/" xlink:type="simple">http://viewer.nationalmap.gov/viewer/</ext-link></p>
<p>The Gateway to Astronaut Photography of Earth (public domain): <ext-link ext-link-type="uri" xlink:href="http://eol.jsc.nasa.gov/sseop/clickmap/" xlink:type="simple">http://eol.jsc.nasa.gov/sseop/clickmap/</ext-link></p>
<p>Maps at the CIA (public domain): <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/the-world-factbook/index.html" xlink:type="simple">https://www.cia.gov/library/publications/the-world-factbook/index.html</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/cia-maps-publications/index.html" xlink:type="simple">https://www.cia.gov/library/publications/cia-maps-publications/index.html</ext-link></p>
<p>NASA Earth Observatory (public domain): <ext-link ext-link-type="uri" xlink:href="http://earthobservatory.nasa.gov/" xlink:type="simple">http://earthobservatory.nasa.gov/</ext-link></p>
<p>Landsat: <ext-link ext-link-type="uri" xlink:href="http://landsat.visibleearth.nasa.gov/" xlink:type="simple">http://landsat.visibleearth.nasa.gov/</ext-link></p>
<p>USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <ext-link ext-link-type="uri" xlink:href="http://eros.usgs.gov/#" xlink:type="simple">http://eros.usgs.gov/#</ext-link></p>
<p>Natural Earth (public domain): <ext-link ext-link-type="uri" xlink:href="http://www.naturalearthdata.com/" xlink:type="simple">http://www.naturalearthdata.com/</ext-link></p>
<p>5. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><!-- <font color="black"> --><bold>Comments to the Author</bold></p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Partly</p>
<p>**********</p>
<p><!-- <font color="black"> -->2. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: N/A</p>
<p>**********</p>
<p><!-- <font color="black"> -->3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p><!-- <font color="black"> -->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p><!-- <font color="black"> -->5. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
<p>Reviewer #1: The World Health Organization (WHO) estimates that seasonal influenza causes a great burden of disease and encourages all nations to establish a Surveillance system that allows for its monitorization and control. In Tanzania, the National Influenza Sentinel Surveillance System (NISSS) was initiated in 2008 and has not since been formally assessed.</p>
<p>Find attached document with comments and suggested changes.</p>
<p>Reviewer #2: In “Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019”, the authors aims at assessing the performances of the sentinel influenza surveillance system implemented in Tanzania. This is a very important topic. Regular evaluation of the existing sentinel surveillance systems allows to continually improve them, and this study is worth publishing. However, the manuscript is not clear enough and not always presented in a logical way. Some information are not given in the introduction or in the methods section to fully understand the message that the authors want to convey.</p>
<p>Avoid the term ‘client’ when talking about ‘patient’ or ‘case’.</p>
<p>Use of semi-comma should be checked throughout the manuscript.</p>
<p>L83: do the authors mean GISRS network?</p>
<p>In the introduction, it would useful to give readers some information about influenza in Tanzania to better understand the epidemic situation. Is influenza seasonal with epidemic peaks or circulating all year-round at lower level?</p>
<p>L178-181 : are we talking about the same three sites? If so, this is a repetition of the selection criteria already mentioned.</p>
<p>The methods section seems to have most of the required information, but the structure could be improved to avoid repetitions and to make things clearer.</p>
<p>There seems to be a mix between the presentation of the results of the surveillance (incidence of influenza and so on) and the evaluation of the surveillance system itself (which would be more about completion of data, performance scores and so on).</p>
<p>The evaluation process is not completely clear. The performances scores and the items taken into consideration as well as the way they were evaluated should be clearly presented. See below about table 4.</p>
<p>Since there is a presentation of the surveillance results (from L212) including the proportion of influenza positive, the laboratory methods used should be detailed in the methods section (PCR? RAT?).</p>
<p>Evaluation of the surveillance system should include the analysis of the proportion of ILI/SARI cases enrolled by each site with regards to the capture population or general data on the site activity (ex for an hospital: total number of patients admitted for any reason). It should also focus on analyzing the age composition of the cases. There is a high proportion of children and the median age very low. This should be analyzed with regards to the population in the region around each site, in order to analyze why the system performs less for adults, for example, and thus be able to propose options to improve the representativeness. Or to discuss this point with regards to cultural practices or socio-economic elements.</p>
<p>Table 1: what is a ‘non-human’ sample?</p>
<p>L218-220: Numbers do not match with Table 1. The proportions are wrong and not calculated on the number of ILI or SARI cases, but on the number of influenza A positives. Which does not really make sense (influenza B among influenza A).</p>
<p>TAT could be one of the criteria to use for the evaluation of the surveillance system. It should probably be analyzed further per site, with regards to the distance to the NIC (if all analyses were performed at the NIC, which is not clear). Here also, so that options to improve TAT could be formulated. This should also be discussed with regards to the goal of the surveillance: is it to provide a diagnosis that will be used in the patient management? Or is it only for surveillance purposes? Not respecting the TAT doesn’t have the same consequence.</p>
<p>English should be checked throughout the manuscript. There are some clumsy sentences. L261-263 is an example. The first sentence starts with ‘although’, which calls for a main clause in the sentence. This main clause is probably the following sentence starting with ‘however’.</p>
<p>L263-264 and Table 2: here is an example showing that not enough information was given in the methods section about the evaluation criteria. Footnote in table 2 gives an indication that 80 samples per month were requested and indeed, presenting the average number of sample per month is an indicator of performance. However, it should perhaps be discussed based on the epidemiological situation and thus, it might vary during the year/season. The proportion of samples taken out of the number of SARI cases is another interesting indicator which calls for more explanation and discussion. It is not clear if the sentinel sites were requested to perform an exhaustive enrollment of ILI and SARI cases or not. It is not clear also how the authors identified the SARI cases when they audited the 3 sentinel sites: what did they use? Here also, follow-up information is needed for the sites that did not reach the target to understand the reasons and be able to propose options for improvement.</p>
<p>The part on Data Quality mixes methods and results. The methods, describing the indicators used for the evaluation and how they were assessed should be presented before and in a clear way.</p>
<p>L330-333: not clear what the authors are talking about.</p>
<p>L333-334: detection of SARS-CoV-2 in 2019? When? How? The first report of SARS-CoV-2 is from December 2019 and specific RT-qPCR assays were available only in January 2020. How did the authors manage to detect SARS-CoV-2?</p>
<p>Statements in the part on representativeness are not supported by data. Given the low numbers of older adults and their susceptibility to influenza, the proportion of older adults seems low and it is not clear whether or not it matches with the population composition.</p>
<p>L368: the definition of Positive Predictive Value is false. The authors are talking about positivity rate. It is not clear how the authors could calculate a true PPV with the data from this study.</p>
<p>L371-373: not clear. Enrollment being based on a clinical definition, it does not mean that all cases are truly infected by influenza viruses. Other pathogens can lead to a similar pattern of symptoms. The use of ILI/SARI definition is only giving a hint of the situation, but only virological testing can confirm the etiology. There is a complementary of the syndromic and virological surveillances. Which confirms that information on the epidemiological context of influenza in Tanzania is missing for the reader to properly evaluate the results.</p>
<p>Table 4 comes far too late. Elements of this table should have been described before in the methods section.</p>
<p>Part of risk factors associated with influenza has nothing to do with the evaluation of the surveillance system. As already mentioned, there is a confusion between the results of the surveillance and its evaluation. The authors states that they are interested in the evaluation of the system, not in the results. The authors must make a choice about what they want to focus on.</p>
<p>Figure 1 is not acceptable for publication.</p>
<p>In general, quality of the figure should be improved.</p>
<p>**********</p>
<p><!-- <font color="black"> -->6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>.<!-- </font> --></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/" xlink:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email xlink:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
<supplementary-material id="pone.0283043.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s006" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">PONE-D-22-16315_review.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0283043.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043.r002</article-id>
<title-group>
<article-title>Author response to Decision Letter 0</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0283043" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj002" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0283043.r001" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">17 Sep 2022</named-content>
</p>
<p>Rebuttal letter </p>
<p>Response to reviewers</p>
<p>We thank the editor and reviewers for evaluating our manuscript. We provide line-by-line responses to comments raised. Please, follow our responses in a green mark. to every comment/question in yellow mark. We copied the review decision from the submission menu of the editorial manager. We used the same letter to write our responses.  </p>
<p>PONE-D-22-16315</p>
<p>Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019.</p>
<p>PLOS ONE</p>
<p>Dear editor,</p>
<p>Pls find the modified manuscript. We have incorporated all suggestions recommended by the reviewers. Following is the point-wise reply to the reviewers' comments.</p>
<p>With best regards,</p>
<p>Mr. Shedura</p>
<p>Reply to comments</p>
<p>Comment:</p>
<p>Dear Dr. Shedura,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please pay particular attention to the structural and textual points raised by the reviewers. Please submit your revised manuscript by Sep 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Response: Thank you for the comments.</p>
<p>Comment:</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
<p>Response: The rebuttal letter has been uploaded as a separate file labeled 'Response to Reviewers'.</p>
<p>Comment:</p>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
<p>Response: The revised marked copy of the manuscript that highlights changes made has been uploaded as a separate file labeled ‘revised Manuscript with track changes’. </p>
<p>Comment:</p>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
<p>Response: Unmarked manuscript without tracked changes has been uploaded as a separate file labeled ‘Manuscript’.</p>
<p>Comment:</p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>Response: We have made no changes in financial disclosure statement. </p>
<p>Comment:</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>Response: We have deposited the laboratory protocols used in protocols.io. We used the updated guidelines for evaluation of the public health surveillance systems, available at <ext-link ext-link-type="uri" xlink:href="https://stacks.cdc.gov/view/cdc/13376" xlink:type="simple">https://stacks.cdc.gov/view/cdc/13376</ext-link>.</p>
<p>Comment:</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Clement Adebajo Meseko, DVM, PhD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p> Response: Thank you for the comments. </p>
<p>Journal Requirements:</p>
<p>Comment:</p>
<p>When submitting your revision, we need you to address these additional requirements.</p>
<p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at </p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and </p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>.</p>
<p>Response: We have modified the style of our manuscript as required by Plos One.</p>
<p>Comment:</p>
<p>2. Please amend your current ethics statement to address the following concerns:</p>
<p>a) Did participants provide their written or verbal informed consent to participate in this study?</p>
<p>Response: We have amended the ethics statement and made clear that the study did not involve direct contact with participants and therefore it based on the verbal consent obtained from patients prior to enrolment into the surveillance. Furthermore; the study was done within the framework of the Integrated Disease Surveillance and Response matrix implemented by the Tanzania Ministry of Health and therefore did not require a formal review by Ethical Review Committees. </p>
<p>Comment:</p>
<p>b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure.</p>
<p>Response:  The evaluation did not involve direct contact with participants and therefore it based on the verbal consent obtained from patients prior to enrolment into the surveillance. Furthermore; the study was done within the framework of the Integrated Disease Surveillance and Response matrix implemented by the Tanzania Ministry of Health and therefore did not require a formal review by Ethical Review Committees. The consent procedures were conducted and approved as per standard procedures of the NISSS.</p>
<p>Comment:</p>
<p>3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" xlink:type="simple">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>. </p>
<p>Response: The raw data in STATA data sheet has been uploaded.</p>
<p>Comment:</p>
<p>In your revised cover letter, please address the following prompts:</p>
<p>a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.</p>
<p>Response: We have revised the cover letter and shared the dataset as required by PLOS ONE.</p>
<p>Comment:</p>
<p>b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <ext-link ext-link-type="uri" xlink:href="http://www.bmj.com/content/340/bmj.c181.long" xlink:type="simple">http://www.bmj.com/content/340/bmj.c181.long</ext-link> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories" xlink:type="simple">http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories</ext-link>.</p>
<p>We will update your Data Availability statement on your behalf to reflect the information you provide.</p>
<p>Response: There are no restrictions. The dataset file is being uploaded as required.</p>
<p>Comment:</p>
<p>4. We note that Figure 1 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/licenses-and-copyright" xlink:type="simple">http://journals.plos.org/plosone/s/licenses-and-copyright</ext-link>.</p>
<p>We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:</p>
<p>a) You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  </p>
<p>We recommend that you contact the original copyright holder with the Content Permission Form (<ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf" xlink:type="simple">http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf</ext-link>) and the following text:</p>
<p>“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">http://creativecommons.org/licenses/by/4.0/</ext-link>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”</p>
<p>Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.</p>
<p>In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”</p>
<p>b) If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.The following resources for replacing copyrighted map figures may be helpful:</p>
<p> USGS National Map Viewer (public domain): <ext-link ext-link-type="uri" xlink:href="http://viewer.nationalmap.gov/viewer/The" xlink:type="simple">http://viewer.nationalmap.gov/viewer/The</ext-link> Gateway to Astronaut Photography of Earth (publicdomain): <ext-link ext-link-type="uri" xlink:href="http://eol.jsc.nasa.gov/sseop/clickmap/" xlink:type="simple">http://eol.jsc.nasa.gov/sseop/clickmap/</ext-link></p>
<p>Maps at the CIA (public domain): <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/the-world-factbook/index.html" xlink:type="simple">https://www.cia.gov/library/publications/the-world-factbook/index.html</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/cia-maps-publications/index.html" xlink:type="simple">https://www.cia.gov/library/publications/cia-maps-publications/index.html</ext-link> NASA Earth Observatory (public domain): <ext-link ext-link-type="uri" xlink:href="http://earthobservatory.nasa.gov/" xlink:type="simple">http://earthobservatory.nasa.gov/</ext-link></p>
<p>Landsat: <ext-link ext-link-type="uri" xlink:href="http://landsat.visibleearth.nasa.gov/" xlink:type="simple">http://landsat.visibleearth.nasa.gov/</ext-link> USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <ext-link ext-link-type="uri" xlink:href="http://eros.usgs.gov/#" xlink:type="simple">http://eros.usgs.gov/#</ext-link></p>
<p>Natural Earth (public domain): <ext-link ext-link-type="uri" xlink:href="http://www.naturalearthdata.com/" xlink:type="simple">http://www.naturalearthdata.com/</ext-link></p>
<p>Response: We have removed the previous Figure 1 on the revised manuscript.</p>
<p>Comment:</p>
<p>5. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.</p>
<p>Response: We have cited Table 4 in the text which has now changed to Table 3 in the revised manuscript.</p>
<p>Academic Editor comments</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Comment:</p>
<p>Instead of the disease, it would be best to name it as Influenza. Instead of the distribution, to be more general here it might be best to say “estimating the burden of disease caused by Influenza virus….” This is only in Tanzania, correct? This should be stated.</p>
<p>Response: We have replaced the word ‘disease’ by ‘Influenza’. We have stated the name of the country (Tanzania) in which the surveillance system was evaluated.</p>
<p>Comment:</p>
<p>It be more clear to start out with: From March to April 2021, we collected data</p>
<p>Response: We have begun the sentence by the phrase “From March to April 2021”, as suggested. </p>
<p>Comment:</p>
<p>No references in abstract</p>
<p>Response: We have removed reference from the abstract. </p>
<p>Comment:</p>
<p>The words “A review of the Influenza Laboratory electronic forms from the Laboratory information system (Disa Lab) showed that” has been stated in the methodology section.</p>
<p>Response: The words “A review of the Influenza Laboratory electronic forms from the Laboratory information system (Disa Lab) showed that” is being removed.</p>
<p>Comment:</p>
<p>What does this TAT relate to? Not mentioned in Methods, Delete from abstract</p>
<p>Response: The Turnaround time (TAT) relates to the timeliness of the Tanzania Influenza surveillance system evaluated. Shorter TAT may lead to timely operations of the system procedures. TAT is one of the timeliness indicators involved in the evaluation of the Influenza surveillance system and we have included it in the method section. This definition has been added in the revised manuscript in page 6</p>
<p>Comment:</p>
<p>Is NPHL- National Public Health Laboratory?</p>
<p>Response: Yes, the abbreviation has been defined in the revised manuscript. </p>
<p>Comment:</p>
<p>“since then, epidemics have been persisting”. There were epidemics before, only they were not recorded. So, since the instauration of the NISSS.” influenza epidemics have been monitored”</p>
<p>Response: The sentence has been rephrased to “since then, epidemics have been reported and monitored”.</p>
<p>Comment:</p>
<p>The words “National Influenza Sentinel Surveillance System (NISSS)”:  It has already been specified, delete (NISSS) or leave and delete National Influenza Sentinel Surveillance System</p>
<p>Response: We have deleted the words “National Influenza Sentinel Surveillance System” in the sentence and replaced them with “NISSS” as suggested. </p>
<p>Comment:</p>
<p>The words “The NISSS cover the entire population of Tanzania, which was approximated to be 56.32 million by 2019”.  This is a sentinel system; how can it be inclusive to the entire population? By definition it would not be a sentinel system then.</p>
<p>Response: We have deleted the sentence.  We have made it clear that: The population under NISSS involves patients enrolled from the fourteen sentinel sites located in eight regions of Tanzania. We have listed the fourteen sentinel sites of the NISSS in Tanzania in the methodology part.</p>
<p>Comment:</p>
<p>Decide whether the participants are to be patients or clients throughout the paper. To me the first option is more adequate</p>
<p>Response: We have decided to use Patients instead of Clients throughout the paper</p>
<p>Comment:</p>
<p>Are these IQR correct? (In the age variable, table 1)</p>
<p>Response: Yes, the IQR are correct. We have shown them clear both median and their interquartile ranges (IQR).</p>
<p>Comment:</p>
<p>About “Non-human sample (Failed results). Can you explain this?</p>
<p>Response: Non-human samples are samples contaminated with PCR inhibitors resulting for their detection as “no-human sample” by RT PCR Machine, and therefore, the influenza virus status in the sample can’t be obtained. We have changed the word to “Failed samples” instead of “Non-human sample”. This clarification has been added in the revised manuscript in page 9 </p>
<p>Comment:</p>
<p>“System attributes”-Consider reducing the description of these items, score results of which are presented on Table 5. And include the information in the discussion section </p>
<p>Response: We have reduced the description of the individual system attributes and included some information in methodology and discussion sections.</p>
<p>Comment:</p>
<p>In system attributes description “Simplicity”. These 2 sentences are not clear</p>
<p>Response: The sentences have been rephrased and made clear.</p>
<p>Comment:</p>
<p>“Table 3”: Consider if really relevant to include in the text (maybe as supplementary material)  </p>
<p>Response: Table 3 in the text has been shifted to supplementary material.</p>
<p>Comment:</p>
<p>“Uncharacterized influenza A viruses into subtypes”. This is a limitation to which of the considered items?</p>
<p>Response:</p>
<p>We have removed the sentence since it is irrelevant to the objectives of the study.</p>
<p>Response to Reviewers’ comments</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p>Comments to the Author</p>
<p>Comment:</p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Partly</p>
<p>Response: Thank you for the comments</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>2. Has the statistical analysis been performed appropriately and rigorously?</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: N/A</p>
<p>Response: Thank you for the comments</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>Response: Thank you for the comments. The STATA file has been uploaded as a supporting information.</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>Response: We have used the standard English in the revised manuscript.</p>
<p>________________________________________</p>
<p>5. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
<p>Comment:</p>
<p>Reviewer #1: The World Health Organization (WHO) estimates that seasonal influenza causes a great burden of disease and encourages all nations to establish a Surveillance system that allows for its monitorization and control. In Tanzania, the National Influenza Sentinel Surveillance System (NISSS) was initiated in 2008 and has not since been formally assessed.</p>
<p>Response: The first National Influenza Sentinel Surveillance System (NISSS) in Tanzania was conducted in 2010 (30 months after the initiation of the surveillance system), and revealed the prevalence of seasonal influenza in Tanzania of 8.0%. We have included this information in the introduction part.  </p>
<p>Comment:</p>
<p>Find attached document with comments and suggested changes.</p>
<p>Response: Thank you for the comments and suggestions. We have reviewed the comments and addressed them. </p>
<p>Comment:</p>
<p>Reviewer #2: In “Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019”, the authors aims at assessing the performances of the sentinel influenza surveillance system implemented in Tanzania. This is a very important topic. Regular evaluation of the existing sentinel surveillance systems allows to continually improve them, and this study is worth publishing. However, the manuscript is not clear enough and not always presented in a logical way. Some information is not given in the introduction or in the methods section to fully understand the message that the authors want to convey.</p>
<p>Response: We have revised the manuscript flow with inclusion of the detailed PCR technique procedures used for the study in the methodology section. </p>
<p>Comment:</p>
<p>Avoid the term ‘client’ when talking about ‘patient’ or ‘case’.</p>
<p>Response: We have used the term ‘patient’ instead of ‘client’ throughout the manuscript.</p>
<p>Comment:</p>
<p>Use of semi-comma should be checked throughout the manuscript.</p>
<p>Response: We have checked-up the use of semi-comma throughout the manuscript.</p>
<p>Comment:</p>
<p>L83: do the authors mean GISRS network?</p>
<p>In the introduction, it would useful to give readers some information about influenza in Tanzania to better understand the epidemic situation. Is influenza seasonal with epidemic peaks or circulating all year-round at lower level?</p>
<p>Response: Yes, we mean ‘Global Influenza Surveillance and Response System (GISRS) Network’. We have corrected the spelling errors. Furthermore; we have included the ‘epidemic situation’ and ‘seasonality of influenza’ in Tanzania in the introduction part. </p>
<p>Comment:</p>
<p>L178-181: are we talking about the same three sites? If so, this is a repetition of the selection criteria already mentioned.</p>
<p>Response:</p>
<p>Thank you for the comment. Yes, we we’re describing the same sites. We have removed them to avoid duplication.</p>
<p>Comment:</p>
<p>The methods section seems to have most of the required information, but the structure could be improved to avoid repetitions and to make things clearer.</p>
<p>There seems to be a mix between the presentation of the results of the surveillance (incidence of influenza and so on) and the evaluation of the surveillance system itself (which would be more about completion of data, performance scores and so on).</p>
<p>The evaluation process is not completely clear. The performances scores and the items taken into consideration as well as the way they were evaluated should be clearly presented. See below about table 4.</p>
<p>Response: We conducted the evaluation of the National Influenza Sentinel Surveillance System (NISSS) in Tanzania, using the CDC updated protocol. Each system attribute was evaluated depending on the indicators shown in Table 4, and as described in the National Influenza Surveillance System protocol of World Health Organization (WHO). The performance scores were set and agreed by the National Influenza Technical working group (NITWG) that includes; public health specialists, Health officers and epidemiologists of the Ministry of Health of Tanzania. </p>
<p>Comment:</p>
<p>Since there is a presentation of the surveillance results (from L212) including the proportion of influenza positive, the laboratory methods used should be detailed in the methods section (PCR? RAT?).</p>
<p>Evaluation of the surveillance system should include the analysis of the proportion of ILI/SARI cases enrolled by each site with regards to the capture population or general data on the site activity (ex for a hospital: total number of patients admitted for any reason). It should also focus on analyzing the age composition of the cases. There is a high proportion of children and the median age very low. This should be analyzed with regards to the population in the region around each site, in order to analyze why the system performs less for adults, for example, and thus be able to propose options to improve the representativeness. Or to discuss this point with regards to cultural practices or socio-economic elements.</p>
<p>Response: We have added the detailed information on PCR technique and procedures used in the methodology part (Laboratory procedures). The description of the age specific ILI/SARI cases is shown in Table 1.  The description of number of patients admitted for ILI/SARI is shown in Table 2.</p>
<p>Comment:</p>
<p>Table 1: what is a ‘non-human’ sample?</p>
<p>Response: Non-human samples are samples contaminated with PCR inhibitors resulting for their detection as “no-human sample” by RT PCR Machine, and therefore, the influenza virus status in the sample can’t be obtained. We have changed the word to “Failed samples” instead of “Non-human sample”. We have shown this in Table 1.</p>
<p>Comment:</p>
<p>L218-220: Numbers do not match with Table 1. The proportions are wrong and not calculated on the number of ILI or SARI cases, but on the number of influenza A positives. Which does not really make sense (influenza B among influenza A).</p>
<p>TAT could be one of the criteria to use for the evaluation of the surveillance system. It should probably be analyzed further per site, with regards to the distance to the NIC (if all analyses were performed at the NIC, which is not clear). Here also, so that options to improve TAT could be formulated. This should also be discussed with regards to the goal of the surveillance: is it to provide a diagnosis that will be used in the patient management? Or is it only for surveillance purposes? Not respecting the TAT doesn’t have the same consequence.</p>
<p>Response: Thank you for the comments. We have corrected the proportions in the revised version of the manuscript. Furthermore; we have added analysis of the Sentinel sites -specific TAT as shown in the current Figure 4.  TAT is both for providing prompt diagnosis to patients under surveillance and for ensuring timely operation of the surveillance activities. We have added TAT information in the methodology and discussion sections.  </p>
<p>Comment:</p>
<p>English should be checked throughout the manuscript. There are some clumsy sentences. L261-263 is an example. The first sentence starts with ‘although’, which calls for a main clause in the sentence. This main clause is probably the following sentence starting with ‘however’.</p>
<p>Response: We have reviewed English and corrected grammatical errors throughout the manuscript.</p>
<p>Comment:</p>
<p>L263-264 and Table 2: here is an example showing that not enough information was given in the methods section about the evaluation criteria. Footnote in table 2 gives an indication that 80 samples per month were requested and indeed, presenting the average number of samples per month is an indicator of performance. However, it should perhaps be discussed based on the epidemiological situation and thus, it might vary during the year/season.</p>
<p>Response: The evaluation criteria has been added in the methodology section. The established average of samples to be collected per site is 80 samples per month in each sentinel site regardless of the epidemiological changes, according to the established protocol for the evaluation of National influenza sentinel surveillance system in Tanzania. </p>
<p>Comment:</p>
<p>The proportion of samples taken out of the number of SARI cases is another interesting indicator which calls for more explanation and discussion. It is not clear if the sentinel sites were requested to perform an exhaustive enrollment of ILI and SARI cases or not. It is not clear also how the authors identified the SARI cases when they audited the 3 sentinel sites: what did they use? Here also, follow-up information is needed for the sites that did not reach the target to understand the reasons and be able to propose options for improvement.</p>
<p>Response: The sentinel sites were not requested to perform an exhaustive enrollment of ILI and SARI cases. The sentinel sites enroll patients who meet the standard case definition for either ILI or SARI. The standard case definitions used (ILI and SARI) are described in the methodology section in page 4 in the inclusion criteria. </p>
<p>Comment:</p>
<p>The part on Data Quality mixes methods and results. The methods, describing the indicators used for the evaluation and how they were assessed should be presented before and in a clear way.</p>
<p>Response: Thank you for the comment on this. We have reviewed the explanation of data quality and separated the results from the methodology information. We have added in the methodology part a description of the indicators used to assess the system attributes of the National Influenza Sentinel surveillance system in Tanzania.</p>
<p>Comment:</p>
<p>L330-333: not clear what the authors are talking about.</p>
<p>L333-334: detection of SARS-CoV-2 in 2019? When? How? The first report of SARS-CoV-2 is from December 2019 and specific RT-qPCR assays were available only in January 2020. How did the authors manage to detect SARS-CoV-2?</p>
<p>Response: Thank you for your insight on this. In L330-334: we meant that NISSS through the established protocol, allows testing of other respiratory viral infections including SARS-CoV-2, and thus not limited to Influenza virus alone. However; we have removed this part from the revised version of the manuscript for more clarity. </p>
<p>Comment:</p>
<p>Statements in the part on representativeness are not supported by data. Given the low numbers of older adults and their susceptibility to influenza, the proportion of older adults seems low and it is not clear whether or not it matches with the population composition.</p>
<p>Response: Sentinel sites were chosen from 8 regions based on population density climatic, and socio diversity in the country so as to facilitate estimation of disease burden in the whole population. Despite the fact that there was unequal distribution of patients of different age, all age category was included in the surveillance and thus being representative. </p>
<p>Comment:</p>
<p>L368: the definition of Positive Predictive Value is false. The authors are talking about positivity rate. It is not clear how the authors could calculate a true PPV with the data from this study.</p>
<p>Response: Thank you for the comments. According to the updated guidelines for evaluating public health surveillance systems available at <ext-link ext-link-type="uri" xlink:href="https://stacks.cdc.gov/view/cdc/13376" xlink:type="simple">https://stacks.cdc.gov/view/cdc/13376</ext-link>.(page 18-20), defines Predictive value positive (PVP) of the surveillance system as the proportion of reported cases that actually have the health-related event under surveillance. For this context, the health-related event under surveillance is Influenza disease. Furthermore; from the cited guideline, the calculation of the PVP is done by using a formula: True positive/ (True positive + False negative). The “True positive” of the surveillance system are those patients who met the standard case definition of either SARI or ILI, depending on their clinical presentations, and therefore enrolled in to the surveillance system, and their PCR results showed positive results of the influenza Virus A or Influenza Virus B. So, in this study such patients were 373 in number. However; the other category of “False positive” of the surveillance system are those patients who met the standard case definitions (SARI/ILI), enrolled in to the surveillance system but their PCR results showed no detection of Influenza virus. For this study such patients were 1348 in number. Therefore; according to the PVP formular; True positive/ (True positive + False negative); PVP=373/ (373+1348) =21.7%. In summary; we calculated the PVP of the Influenza surveillance system and not PVP of the influenza test. We have corrected some errors during the calculation in the revised manuscript. </p>
<p>Comment:</p>
<p>L371-373: not clear. Enrollment being based on a clinical definition; it does not mean that all cases are truly infected by influenza viruses. Other pathogens can lead to a similar pattern of symptoms. The use of ILI/SARI definition is only giving a hint of the situation, but only virological testing can confirm the etiology. There is a complementary of the syndromic and virological surveillances. Which confirms that information on the epidemiological context of influenza in Tanzania is missing for the reader to properly evaluate the results.</p>
<p>Response: Thank you for the comments. The National Influenza Sentinel Surveillance System in Tanzania is flexible, and allows the investigation of other viral respiratory infections apart from Influenza, which may show similar clinical presentation during the time of enrolment. We have described the epidemiological trend of influenza in Tanzania at the introduction part of the revised manuscript in page 2. </p>
<p>Comment:</p>
<p>Table 4 comes far too late. Elements of this table should have been described before in the methods section.</p>
<p>Part of risk factors associated with influenza has nothing to do with the evaluation of the surveillance system. As already mentioned, there is a confusion between the results of the surveillance and its evaluation. The authors states that they are interested in the evaluation of the system, not in the results. The authors must make a choice about what they want to focus on.</p>
<p>Response: Thank you for this comment. We have added description of the evaluation elements in the methodology section. We mainly aimed to evaluate the surveillance system, and therefore, we have removed the part of risk factors in the revised manuscript. </p>
<p>Comment:</p>
<p>Figure 1 is not acceptable for publication.</p>
<p>In general, quality of the figure should be improved.</p>
<p>Response: Thank you for the comment. We have removed Figure 1 and listed down the sentinel sites of NISSS in the methodology part.  The Figure 4 in the revised manuscript involves the description of TAT coverage in each sentinel sites of the NISSS in Tanzania as suggested. </p>
<p>________________________________________</p>
<p>Comment:</p>
<p>6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.</p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>Response: Thank you for the comments. </p>
<p>________________________________________</p>
<p> Comment:</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/" xlink:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email xlink:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
<p> Response: Thank you.</p>
<p>NB: We have made some changes in the order of figures, tables and supporting information.</p>
<p>Figures:</p>
<p>Fig 1 removed, Fig 2 has changed to Fig 1, Fig 3 has changed to Fig 2, Fig 4 has changed to Fig 3 and the new Fig 4 added. </p>
<p>Tables:</p>
<p> Tables, 3 and 5 are removed and table 4 has changed to Table 3. </p>
<p>Supporting information:</p>
<p> We have added S3_File and S4_ File.</p>
<supplementary-material id="pone.0283043.s007" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s007" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Rebuttal Letter_Response to Reviewers.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0283043.r003" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043.r003</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Meseko</surname>
<given-names>Clement Adebajo</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>Clement Adebajo Meseko</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0283043" document-id-type="doi" document-type="article" id="rel-obj003" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">13 Dec 2022</named-content>
</p>
<p><!-- <div> -->PONE-D-22-16315R1<!-- </div> --><!-- <div> -->Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019<!-- </div> --><!-- <div> -->PLOS ONE</p>
<p>Dear Dr. Shedura,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>​Please submit your revised manuscript by Jan 27 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"> <list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item> <list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item> <list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list><!-- <div> -->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Clement Adebajo Meseko, DVM, PhD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal Requirements:</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p>Additional Editor Comments:</p>
<p>The manuscript is an important public health surveillance data for influenza and other respiratory viruses but still in need of clarity and improvement including grammar. Note the comments by both reviewers that subtype H5 is not a seasonal influenza and it is important to clarify if this is a valid detection because of the importance of H5 in global public health and influenza virus reporting to the WHO.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><!-- <font color="black"> --><bold>Comments to the Author</bold></p>
<p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.<!-- </font> --></p>
<p>Reviewer #1: All comments have been addressed</p>
<p>Reviewer #2: (No Response)</p>
<p>**********</p>
<p><!-- <font color="black"> -->2. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p><!-- <font color="black"> -->3. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p><!-- <font color="black"> -->4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p><!-- <font color="black"> -->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p><!-- <font color="black"> -->6. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
<p>Reviewer #1: Line 132 All specimens positive for influenza A virus were subtyped for seasonal H1(A[H1], H3(A[H3]), H5(A[H5]) and A(H1N1) pdm09</p>
<p>The () are not correctly distributed and H5 is not a seasonal subtype but avian , it should read :All specimens positive for influenza A virus were subtyped for H1, H3, H5 and H1N1pdm09</p>
<p>Yet is this really so? H5 subtyping is carried out in sentinell seasonal influenza surveillance?</p>
<p>Reviewer #2: English needs to be reviewed, especially in modified text (in red in manuscript with corrections). New or rewritten parts need to be checked thoroughly . The sentences are sometimes clumsy.</p>
<p>The description of the evaluation criteria is very useful and enhances greatly the manuscript. The authors should however now work on simplifying the manuscript. Perhaps that the criteria and the results could be extensively presented in a table (i.e. table 3 with additional information if needed), but maybe less extensively in the text.</p>
<p>“clients” is still used several times in the manuscript.</p>
<p>Laboratory procedures: H5 is not considered as a seasonal human influenza viruses.</p>
<p>Predictive Positive Value: it is still not clear how the authors were able to calculate this. This would require to have the number of influenza positive and negative samples among cases (matching the case definitions) and non-cases. The surveillance system aims at enrolling only cases. The authors have thus access only to True Positive and False Negative (what the authors wrongly call False Positive).</p>
<p>The manuscript is really focusing on a major aspect of surveillance: its evaluation. There are not many papers providing such an evaluation, so the manuscript is really important for the scientific community involved in public health surveillance of influenza and other respiratory viruses. It is so important in fact, that it is worth for the authors to take a bit more time to make their manuscript as clear and easy to follow as possible. As such, the content is ok, but the form can be improved in order to avoid too long sentences and to correct the grammar. The clarity of the message will gain from a more synthetic presentation.</p>
<p>**********</p>
<p><!-- <font color="black"> -->7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>.<!-- </font> --></p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/" xlink:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email xlink:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0283043.r004">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043.r004</article-id>
<title-group>
<article-title>Author response to Decision Letter 1</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0283043" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj004" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0283043.r003" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">4 Jan 2023</named-content>
</p>
<p>Rebuttal letter </p>
<p>Response to reviewers</p>
<p>We thank the editor and reviewers for evaluating our manuscript. We provide line-by-line responses to comments raised. Please, follow our responses in a green mark. to every comment/question in yellow mark. We copied the review decision from the submission menu of the editorial manager. We used the same letter to write our responses.  </p>
<p>PONE-D-22-16315R1</p>
<p>Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019.</p>
<p>PLOS ONE</p>
<p>Dear Editor,</p>
<p>Please find the modified manuscript. We have incorporated all suggestions recommended by the reviewers. Following is the point-wise reply to the reviewers' comments.</p>
<p>With best regards,</p>
<p>Mr. Shedura</p>
<p>Reply to comments</p>
<p>Comment:</p>
<p>Dear Dr. Shedura,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please submit your revised manuscript by Jan 27 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email xlink:type="simple">plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Response: Thank you for the comments.</p>
<p>Comment:</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
<p>Response: The rebuttal letter has been uploaded as a separate file labeled 'Response to Reviewers'.</p>
<p>Comment:</p>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
<p>Response: The revised marked copy of the manuscript that highlights changes made has been uploaded as a separate file labeled ‘revised Manuscript with track changes. </p>
<p>Comment:</p>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
<p>Response: Unmarked manuscript without tracked changes has been uploaded as a separate file labeled ‘Manuscript’.</p>
<p>Comment:</p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>Response: We have made no changes in financial disclosure statement. </p>
<p>Comment:</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>Response: We have deposited the laboratory protocols used in protocols.io. We used the updated guidelines for evaluation of the public health surveillance systems, available at <ext-link ext-link-type="uri" xlink:href="https://stacks.cdc.gov/view/cdc/13376" xlink:type="simple">https://stacks.cdc.gov/view/cdc/13376</ext-link>.</p>
<p>Comment:</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Clement Adebajo Meseko, DVM, PhD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p> Response: Thank you for the comments. </p>
<p>Journal Requirements:</p>
<p>Comment:</p>
<p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p> Response: The references have been reviewed.  </p>
<p>Additional Editor Comments:</p>
<p>Comment:</p>
<p>The manuscript is an important public health surveillance data for influenza and other respiratory viruses but still in need of clarity and improvement including grammar. Note the comments by both reviewers that subtype H5 is not a seasonal influenza and it is important to clarify if this is a valid detection because of the importance of H5 in global public health and influenza virus reporting to the WHO.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p> Response: It is true that H5 subtype is Avian not seasonal influenza, thank you for this observation. Although it was part of the included investigations, we have decided to exclude it so as to align with the objectives of our study.  We have stated that the Influenza subtype involved are H1, H3 and H1N1pdm09. </p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p>Comments to the Author</p>
<p>Comment:</p>
<p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.</p>
<p>Reviewer #1: All comments have been addressed</p>
<p>Reviewer #2: (No Response)</p>
<p>Response: Thank you for the comments</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>Response: Thank you for the comments</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously?</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>Response: Thank you for the comments</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>Response: Thank you for the comments</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: No</p>
<p>Response: Thank you for the comments. We have corrected all typographical and grammatical errors in the revised manuscript. </p>
<p>________________________________________</p>
<p>Comment:</p>
<p>6. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
<p>Reviewer #1: Line 132 All specimens positive for influenza A virus were subtyped for seasonal H1(A[H1], H3(A[H3]), H5(A[H5]) and A(H1N1) pdm09</p>
<p>The () are not correctly distributed and H5 is not a seasonal subtype but avian, it should read :All specimens positive for influenza A virus were subtyped for H1, H3, H5 and H1N1pdm09</p>
<p>Yet is this really so? H5 subtyping is carried out in sentinel seasonal influenza surveillance?</p>
<p>Response: It is true that H5 subtype is avian not seasonal influenza, thank you for this observation. Although it was part of the included investigations, we have decided to exclude it so as to align with the objective of our study.  We have stated that the Influenza subtype involves H1, H3, and H1N1pdm09. </p>
<p>Comment:</p>
<p>Reviewer #2: English needs to be reviewed, especially in modified text (in red in manuscript with corrections). New or rewritten parts need to be checked thoroughly. The sentences are sometimes clumsy.</p>
<p>The description of the evaluation criteria is very useful and enhances greatly the manuscript. The authors should however now work on simplifying the manuscript. Perhaps that the criteria and the results could be extensively presented in a table (i.e. table 3 with additional information if needed), but maybe less extensively in the text.</p>
<p>Response: Thank you for the comments. We have corrected all typographical and grammatical errors in the revised manuscript. We have simplified the Manuscript in the revised version.  </p>
<p>Comment:</p>
<p>“clients” is still used several times in the manuscript.</p>
<p>Laboratory procedures: H5 is not considered as a seasonal human influenza viruses.</p>
<p>Response: We have removed the word “clients” throughout the manuscript and replaced it with the word “patents”. We have removed the avian influenza subtype (H5) in the revised manuscript to make it clear pertaining to seasonal influenza sentinel surveillance. </p>
<p>Comment:</p>
<p>Predictive Positive Value: it is still not clear how the authors were able to calculate this. This would require to have the number of influenza positive and negative samples among cases (matching the case definitions) and non-cases. The surveillance system aims at enrolling only cases. The authors have thus access only to True Positive and False Negative (what the authors wrongly call False Positive).</p>
<p>Response: Thank you for the comments. It is true that the surveillance system aims at enrolling only cases, but in influenza surveillance, there are suspected cases and confirmed cases. All cases enrolled in NISSS are suspected cases of influenza that meet either the ILI or SARI case definition. Samples are drawn from all suspected cases for laboratory confirmation and those who will be detected positive are the confirmed cases (true positives) and those who will detect negative after confirmation are the “false positives”. According to the updated guidelines for evaluating public health surveillance systems available at <ext-link ext-link-type="uri" xlink:href="https://stacks.cdc.gov/view/cdc/13376" xlink:type="simple">https://stacks.cdc.gov/view/cdc/13376</ext-link>.(pages; 18-20), defines the Predictive value positive (PVP) of the surveillance system as the proportion of reported cases that actually have the health-related event under surveillance. For this context, the health-related event under surveillance is Influenza disease. Furthermore; from the cited guideline, the calculation of the PVP is done by using a formula: True positive/ (True positive + False negative). The “True positive” of the surveillance system are those patients who met the standard case definition of either SARI or ILI, depending on their clinical presentations, and therefore enrolled in to the surveillance system, and their PCR results showed positive results of the influenza Virus A or Influenza Virus B. So, in this study such patients were 373 in number. However; the other category of “False positive” of the surveillance system are those patients who met the standard case definitions (SARI/ILI), enrolled in to the surveillance system but their PCR results showed no detection of Influenza virus. For this study such patients were 1348 in number. Therefore; according to the PVP formular; True positive/ (True positive + False negative); PVP=373/ (373+1348) =21.7%. In summary; we calculated the PVP of the Influenza surveillance system and not PVP of the influenza test. </p>
<p>Comment:</p>
<p>The manuscript is really focusing on a major aspect of surveillance: its evaluation. There are not many papers providing such an evaluation, so the manuscript is really important for the scientific community involved in public health surveillance of influenza and other respiratory viruses. It is so important in fact, that it is worth for the authors to take a bit more time to make their manuscript as clear and easy to follow as possible. As such, the content is ok, but the form can be improved in order to avoid too long sentences and to correct the grammar. The clarity of the message will gain from a more synthetic presentation.</p>
<p>Response: Thank you for the comments.</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. </p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p>Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.</p>
<p>Reviewer #1: No</p>
<p>Reviewer #2: No</p>
<p>Response: Thank you for the comments.</p>
<p>________________________________________</p>
<p>Comment:</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/" xlink:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email xlink:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
<p>Response: Thank you.</p>
<supplementary-material id="pone.0283043.s008" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0283043.s008" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Rebuttal Letter_Response to Reviewers.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0283043.r005" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043.r005</article-id>
<title-group>
<article-title>Decision Letter 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Meseko</surname>
<given-names>Clement Adebajo</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>Clement Adebajo Meseko</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0283043" document-id-type="doi" document-type="article" id="rel-obj005" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>2</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">1 Mar 2023</named-content>
</p>
<p>Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019</p>
<p>PONE-D-22-16315R2</p>
<p>Dear Dr. Shedura,</p>
<p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
<p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
<p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/" xlink:type="simple">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email xlink:type="simple">authorbilling@plos.org</email>.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email xlink:type="simple">onepress@plos.org</email>.</p>
<p>Kind regards,</p>
<p>Clement Adebajo Meseko, DVM, PhD</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0283043.r006" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0283043.r006</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Meseko</surname>
<given-names>Clement Adebajo</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2023</copyright-year>
<copyright-holder>Clement Adebajo Meseko</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0283043" document-id-type="doi" document-type="article" id="rel-obj006" link-type="peer-reviewed-article"/>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">12 Mar 2023</named-content>
</p>
<p>PONE-D-22-16315R2 </p>
<p>Evaluation of the influenza-like illness sentinel surveillance system: A national perspective in Tanzania from January to December 2019 </p>
<p>Dear Dr. Shedura:</p>
<p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
<p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email xlink:type="simple">onepress@plos.org</email>.</p>
<p>If we can help with anything else, please email us at <email xlink:type="simple">plosone@plos.org</email>. </p>
<p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
<p>Kind regards, </p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. Clement Adebajo Meseko </p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
</body>
</sub-article>
</article>